Biogen Pharmachem Industries (531752) Q3 24/25 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter and nine months ended December 31, 2024.

• Key management changes: appointment of Mr. Kelash Bunkar as Whole-time Director & CFO, resignation of Mr. Niraj Vaghela (Whole-time Director & CFO), appointment of Mr. Aman Patel as Non-Executive Independent Director, and resignation of Ms. Komal Chauhan (Independent Director), all effective February 5, 2025.

Financial highlights

• Revenue from operations for Q3 FY25 was Rs. 22.76 lakhs, compared to Rs. 9.24 lakhs in Q2 FY25 and Rs. 160.22 lakhs in Q3 FY24.

• Net loss for Q3 FY25 stood at Rs. 31.49 lakhs, versus a net profit of Rs. 6.23 lakhs in Q2 FY25 and Rs. 118.93 lakhs in Q3 FY24.

• For the nine months ended December 31, 2024, total income was Rs. 65.05 lakhs, with a net loss of Rs. 99.73 lakhs, compared to total income of Rs. 238.15 lakhs and net profit of Rs. 193.07 lakhs for the same period last year.

• Basic and diluted EPS for Q3 FY25 was Rs. (0.00), compared to Rs. 0.00 in Q2 FY25 and Rs. 0.02 in Q3 FY24.

Outlook and guidance

• Financial results reviewed by the Audit Committee and approved by the Board; statutory auditors conducted a limited review and found no material misstatements.